Mosapride Citrate , ≥98% , 112885-42-4

CAS NO.：112885-42-4

Empirical Formula: C27H33ClFN3O10

Molecular Weight: 614.02

MDL number: MFCD00874415

EINECS: 601-211-6

PRODUCT Properties

• Melting point: 143-145°
• storage temp.: Inert atmosphere,2-8°C
• solubility: DMSO (Slightly), Ethanol (Slightly, Sonicated)
• form: Solid
• color: White to Off-White
• Stability: Hygroscopic
• InChIKey: HUZTYZBFZKRPFG-UHFFFAOYSA-N
• SMILES: C(O)(C(=O)O)(CC(=O)O)CC(=O)O.C(C1C=C(Cl)C(N)=CC=1OCC)(=O)NCC1OCCN(CC2C=CC(F)=CC=2)C1
• CAS DataBase Reference: 112885-42-4(CAS DataBase Reference)

Description and Uses

Mosapride is an agonist of the serotonin (5-HT) receptor subtype 5-HT₄ (K_i = 69.9 nM). It is selective for 5-HT₄ over 5-HT₁, 5-HT₂, dopamine D₂, and α₁- and α₂-adrenergic receptors but acts as a partial antagonist at 5-HT₃ (K_i = 1,189 nM). It induces relaxation of precontracted rat esophageal thoracic muscularis mucosa preparations and enhances electrically evoked contractions in isolated guinea pig ileum (EC₅₀s = 208.4 and 73.2 nM, respectively). Mosapride (0.5 and 1 mg/kg, i.v.) increases antral and duodenal, but not ileal or colonic, motility in conscious dogs. It also increases gastric emptying in rats when administered at doses ranging from 0.03 to 30 mg/kg.

As a selective SR-4 activator and a SR-3 inhibitor, Mosapride(Mosapride citrate) is a gastroprokinetic agent that acts as a selective 5HT4 agonist which accelerates gastric emptying and is used for the treatment of acid reflux, irritable bowel syndrome and functional dyspepsia.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H332-H335
• Precautionary statements: P280-P305+P351+P338-P310
• Toxicity: LD50 in male, female mice, rats (mg/kg): >3000, >3000, >3000, 1905 orally; >1000, 914, >1000, >1000 i.p.; all species >1000 s.c.; in male, female dogs (mg/kg): both >400 orally (Yatera)